Venture Capital

We represent regional, national and international venture capital firms that invest in early-stage companies across a range of industries, most notably in software, communications and telecommunications, therapeutics, medical devices and energy sectors. We help venture capital investment professionals deal with the many contingencies that arise in transactions such as portfolio investments, liquidity events, corporate governance and compliance matters, intellectual property and other due diligence-review services. These cases/issues often involve the comprehensive assessment of complex patent portfolios and strategy. We also work with venture capital firms on fund formation and fund-raising efforts, and regularly advise institutions making investments in venture capital funds. We have negotiated investment terms with scores of venture capital firms around the world.

A key strength is our ability to provide our investment clients with early access to entrepreneurs and emerging companies, particularly in pan-European technology sector companies located in Ireland and Israel. Our expertise across the full range of investment and fund formation issues combined with our pragmatic business advice makes us the ideal partner for venture capitalists.

Representative Client Work

• Represented a Massachusetts-focused seed and early-stage venture firm in numerous portfolio company investments in the software, communications, life sciences and material sciences sectors
• Assisted major financial services firm in strategic venture investments of more than $225 million in international telecommunications companies
• Represented a group of venture capital investors in financing rounds aggregating $21.5 million in early-stage funding for a medical technology company developing an innovative, percutaneous approach for delivering heart valves to treat late-stage aortic stenosis
• Represented a leading venture capital fund with more than $1.6 billion in committed capital under management; facilitated the fund's first "going-private" transaction with a publicly-traded enterprise
• Represented a venture capital firm in connection with due diligence analyses related to a number of medical device technologies, including spinal implants, ocular lens implants, vascular grafts, aortic valve replacements and cardiac ablation devices
• Represented a syndicate of life sciences venture capital firms in a series of multi-million dollar bridge financings followed by a $4.4 million financing round and recapitalization for a developer of disposable catheter products for the treatment of cardiovascular disorders using laser energy